IHMRI affiliation

Theme:Diagnostics and therapeutics
Level:Honorary IHMRI Fellow

Research focus

  • Medical oncology
  • Clinical trials
  • Cancer

Publications and funding

  • L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gumus. J. Mazieres,• L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gumus. J. Mazieres,B. Hermes, F. Cay Senler, T. Csaszi. A Fulop, J. Rodriguez-Cid, J Wilson, S. Sugawara, T. Kato, K.H. Lee, Y_ Cheng, S. Novello, B. Halmos, X. Li. G.M. Lubiniecki. B. Piperdi, and D.M. Kowalski. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine 25 September 2018
  • Julie R Brahmer, Delvys Rodriguez-Abreu, Andrew G Robinson. Rina Hui, Tibor Csoszi, Andrea Fulop, Maya Gottfried, Prof Nir Peled. Ali Tafreshi, Sinead Cuffe, Mary O’Brien. Suman Rao, Katsuyuki Hatta, Jin Zhang, Gregory M Lubiniecki, Anne C Deitz, Reshma Rangwala, Martin Reck. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncology. November 2017 
  •  Martin Reck, Delvys Rodriguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csoszi, Andrea Fulop, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, and Julie R. Brahmer. KEYNOTE-024: Pembrolizumab vs Platinum-Based Chemotherapy as First-Line Therapy for Advanced NSCLC With a PD-L 1 TPS  ≥ 50%. New England Journal of Medicine 9 October 2015
  • Ali Tafreshi, Eddy Thientosapol, Mun Sem Liew, Yuan Guo. Melissa Quaggiotto. Michael Boyer. and Ian D Davis. Efficacy of sorafenib in advanced renal cell carcinoma (RCC) independent of prior treatment, histology or prognostic group. Asia-Pacific Journal of Clinical Oncology March 2014

Other roles

  • Clinical Associate Professor, School of Medicine, University of Wollongong